ContraFect_LOGO_Web.jpg
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
18 sept. 2023 07h30 HE | ContraFect Corporation
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 08h00 HE | ContraFect Corporation
YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria
14 nov. 2016 07h00 HE | ContraFect Corporation
YONKERS, NY--(Marketwired - November 14, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...